Immunic, Inc.(IMUX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

IMUX Immunic, Inc.

Market Closed 10-30 16:00:00 EDT

7.51

-0.28

-3.66%

盘后7.62

+0.11+1.46%

19:30 EDT

High7.78	Low7.37	Vol244.43K
Open7.70	D1 Closing7.80	Amplitude5.26%
Mkt Cap102.14M	Tradable Cap90.19M	Total Shares13.60M
T/O1.83M	T/O Rate2.04%	Tradable Shares12.01M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"IMUX","market":"US","secType":"STK","nameCN":"Immunic, Inc.","latestPrice":7.51,"timestamp":1793390400000,"preClose":7.795,"halted":0,"volume":244425,"hourTrading":{"tag":"盘后","latestPrice":7.62,"preClose":7.51,"latestTime":"19:30 EDT","volume":337,"amount":2567.51,"timestamp":1793403001954,"change":0.11,"changeRate":0.014647,"amplitude":0.014647},"delay":0,"changeRate":-0.0365618986529827,"floatShares":12009900,"shares":13600000,"eps":-3.997894,"marketStatus":"Market Closed","change":-0.285,"latestTime":"10-30 16:00:00 EDT","open":7.7,"high":7.78,"low":7.37,"amount":1833852.43377,"amplitude":0.052598,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-3.997894,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1793610000000},"marketStatusCode":7,"adr":0,"adrRate":0,"listingDate":1397707200000,"exchange":"NASDAQ","adjPreClose":7.795,"preHourTrading":{"tag":"盘前","latestPrice":7.68,"preClose":7.795,"latestTime":"09:29 EDT","volume":1100,"amount":8251.59984,"timestamp":1793366999999,"change":-0.115,"changeRate":-0.014753,"amplitude":0.047723},"postHourTrading":{"tag":"盘后","latestPrice":7.62,"preClose":7.51,"latestTime":"19:30 EDT","volume":337,"amount":2567.51,"timestamp":1793403001954,"change":0.11,"changeRate":0.014647,"amplitude":0.014647},"volumeRatio":0.7557365479879767,"impliedVol":2.1167,"impliedVolPercentile":0.896},"requestUrl":"/m/hq/s/IMUX/wiki","defaultTab":"wiki","newsList":[{"id":"2679472205","title":"Immunic Hosts Progressive Multiple Sclerosis R&D Day","url":"https://stock-news.laohu8.com/highlight/detail?id=2679472205","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2679472205?lang=en_us&edition=fundamental","pubTime":"2026-10-29 18:30","pubTimestamp":1793269831,"startTime":"0","endTime":"0","summary":"Immunic Hosts Progressive Multiple Sclerosis R&D DayImmunic will host a virtual progressive multiple sclerosis R&D Day on November 5, 2026, at 12:30 p.m. ET.Discussions will focus on vidofludimus calc","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261029:nNDL214zCP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","IMUX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2677192995","title":"Cantor Fitzgerald Initiates Coverage on Immunic With Overweight Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2677192995","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2677192995?lang=en_us&edition=fundamental","pubTime":"2026-10-23 19:26","pubTimestamp":1792754803,"startTime":"0","endTime":"0","summary":"Immunic (IMUX) has an average rating of buy and mean price target of $43.09, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from major banks and r","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["IMUX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2677926705","title":"Immunic Initiated at Overweight by Cantor Fitzgerald","url":"https://stock-news.laohu8.com/highlight/detail?id=2677926705","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2677926705?lang=en_us&edition=fundamental","pubTime":"2026-10-23 19:11","pubTimestamp":1792753860,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/IMUX/analyst-ratings","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IMUX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2677467387","title":"Immunic's Vidofludimus Calcium Shows Sustained Disability Outcome Trends in Phase 2 MS Extension Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2677467387","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2677467387?lang=en_us&edition=fundamental","pubTime":"2026-10-21 19:01","pubTimestamp":1792580461,"startTime":"0","endTime":"0","summary":"Immunic's Vidofludimus Calcium Shows Sustained Disability Outcome Trends in Phase 2 MS Extension StudyImmunic reported sustained disability outcome trends with continued vidofludimus calcium treatment","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261021:nNDL8lbhjC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","IMUX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2677678077","title":"Eqs-News: Immunic Presents New Clinical, Biomarker, and Preclinical Data for Vidofludimus Calcium in Four Poster Presentations at Mstoronto2026 – the 10TH Joint Actrims-Ectrims Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2677678077","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2677678077?lang=en_us&edition=fundamental","pubTime":"2026-10-21 19:00","pubTimestamp":1792580407,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261021:nTUC5W4VB9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["IMUX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2676683326","title":"Immunic Expects Funding to Last into Late 2027","url":"https://stock-news.laohu8.com/highlight/detail?id=2676683326","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2676683326?lang=en_us&edition=fundamental","pubTime":"2026-10-19 19:40","pubTimestamp":1792410051,"startTime":"0","endTime":"0","summary":"Immunic Expects Funding to Last Into Late 2027Immunic expects funding to last into late 2027.Two fully enrolled Phase 3 trials of vidofludimus calcium, totaling 2,221 patients, are expected to deliver","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261019:nNDL9pGC3X:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IMUX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2676079955","title":"Immunic Appoints Jaa Roberson as Chief People Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2676079955","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2676079955?lang=en_us&edition=fundamental","pubTime":"2026-10-19 18:30","pubTimestamp":1792405802,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261019:nTUAC6L2RB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","IMUX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2675175353","title":"Immunic Grants Inducement Stock Options for 12,900 Shares to Three New Employees Under 2026 Plan","url":"https://stock-news.laohu8.com/highlight/detail?id=2675175353","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2675175353?lang=en_us&edition=fundamental","pubTime":"2026-10-13 18:31","pubTimestamp":1791887471,"startTime":"0","endTime":"0","summary":"Immunic grants inducement stock options for 12,900 shares to three new employees under 2026 planImmunic granted inducement stock options covering 12,900 common shares to three new employees on Oct. 1,","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261013:nNDL1xCZfC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","IMUX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2675539723","title":"Immunic Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)","url":"https://stock-news.laohu8.com/highlight/detail?id=2675539723","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2675539723?lang=en_us&edition=fundamental","pubTime":"2026-10-13 18:30","pubTimestamp":1791887402,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261013:nTUA5R25TS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","IMUX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673090429","title":"Immunic Reports Calliper Extension Data Showing Sustained Disability Outcomes for Vidofludimus Calcium in Progressive MS Through Week 48","url":"https://stock-news.laohu8.com/highlight/detail?id=2673090429","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673090429?lang=en_us&edition=fundamental","pubTime":"2026-10-07 20:01","pubTimestamp":1791374475,"startTime":"0","endTime":"0","summary":"Immunic reports CALLIPER extension data showing sustained disability outcomes for vidofludimus calcium in progressive MS through week 48Immunic flagged new Phase 2 CALLIPER open-label extension result","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261007:nNDL504m0G:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","IMUX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673090104","title":"Eqs-News: Immunic to Present New Clinical, Biomarker and Preclinical Data on Vidofludimus Calcium at Mstoronto2026 – the 10TH Joint Actrims-Ectrims Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2673090104","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673090104?lang=en_us&edition=fundamental","pubTime":"2026-10-07 20:00","pubTimestamp":1791374407,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261007:nTUC1BN3PH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","IMUX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673704792","title":"We Think Immunic (NASDAQ:IMUX) Needs To Drive Business Growth Carefully","url":"https://stock-news.laohu8.com/highlight/detail?id=2673704792","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673704792?lang=en_us&edition=fundamental","pubTime":"2026-10-05 18:15","pubTimestamp":1791195335,"startTime":"0","endTime":"0","summary":"Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...","market":"sg","thumbnail":"https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/industry/6111000-choice2-card/1788928698944","type":0,"news_type":0,"thumbnails":["https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/industry/6111000-choice2-card/1788928698944"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-imux/immunic/news/we-think-immunic-nasdaqimux-needs-to-drive-business-growth-c","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-imux/immunic/news/we-think-immunic-nasdaqimux-needs-to-drive-business-growth-c","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["QQQA","MNQmain","QID","NQmain","JEPQ","QLD","TQQQ","IMUX","NDX","ONEQ","SQQQ","QQQJ","IYW","NVIW.SI","QYLG","03086","TQQY","QQQ","PSQ","QQQY","QDTE","QQQM","FTEC","BK4139","TECS",".IXIC","GPIQ","QQQE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671242173","title":"Immunic Grants Options for 196,350 Shares to Seven New Hires Under Inducement Equity Plan","url":"https://stock-news.laohu8.com/highlight/detail?id=2671242173","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2671242173?lang=en_us&edition=fundamental","pubTime":"2026-09-30 04:05","pubTimestamp":1790712321,"startTime":"0","endTime":"0","summary":"Immunic grants options for 196,350 shares to seven new hires under inducement equity planImmunic granted inducement stock options covering 196,350 common shares to seven new employees between Sept. 14","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260929:nNDL9gfcJz:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","IMUX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666572532","title":"Immunic Director Duane Nash Resigns, Board Shrinks to Nine Members","url":"https://stock-news.laohu8.com/highlight/detail?id=2666572532","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666572532?lang=en_us&edition=fundamental","pubTime":"2026-09-12 05:25","pubTimestamp":1789161922,"startTime":"0","endTime":"0","summary":"Immunic director Duane Nash resigns, board shrinks to nine membersImmunic director Duane Nash resigned from the board on Sept. 10, 2026.Board size reduced to nine members from 10.Disclaimer:This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immunic Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on September 11, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260911:nNDL4r8Rwb:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IMUX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666599699","title":"Leerink Partners Sticks to Its Buy Rating for Immunic (IMUX)","url":"https://stock-news.laohu8.com/highlight/detail?id=2666599699","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666599699?lang=en_us&edition=fundamental","pubTime":"2026-09-10 21:25","pubTimestamp":1789046740,"startTime":"0","endTime":"0","summary":"In a report released today, from Leerink Partners maintained a Buy rating on Immunic, with a price target of $12.19. Currently, the analyst consens...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/leerink-partners-sticks-to-its-buy-rating-for-immunic-imux-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/leerink-partners-sticks-to-its-buy-rating-for-immunic-imux-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IMUX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666356779","title":"Analysts Are Bullish on These Healthcare Stocks: Immunic (IMUX), Celldex (CLDX)","url":"https://stock-news.laohu8.com/highlight/detail?id=2666356779","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666356779?lang=en_us&edition=fundamental","pubTime":"2026-09-10 18:50","pubTimestamp":1789037412,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Immunic (IMUX), Celldex (CLDX) and Cooper Co (COO) w...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-these-healthcare-stocks-immunic-imux-celldex-cldx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-these-healthcare-stocks-immunic-imux-celldex-cldx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0128526141.USD","HCSG","LU1992135472.HKD","LU2211815571.USD","BK4581","XLV","LU2272731600.USD","BK4588","IMUX","LU1992135399.USD","LU2272731782.SGD","LU0029874061.USD","CLDX","XBI","GB00BDT5M118.USD","BK4137","COO","BK4585","BK4139","LABU","BK4198"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666718562","title":"Immunic Price Target Maintained with a $22.00/Share by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2666718562","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666718562?lang=en_us&edition=fundamental","pubTime":"2026-09-10 18:22","pubTimestamp":1789035720,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/IMUX/analyst-ratings","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IMUX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666529536","title":"Immunic Highlights Multiple Sclerosis Program in R&D Webinar","url":"https://stock-news.laohu8.com/highlight/detail?id=2666529536","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666529536?lang=en_us&edition=fundamental","pubTime":"2026-09-09 21:30","pubTimestamp":1788960631,"startTime":"0","endTime":"0","summary":"Immunic ( ($IMUX) ) just unveiled an announcement. On September 9, 2026, Immunic hosted a Relapsing Multiple Sclerosis Research and Development Day...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/immunic-highlights-multiple-sclerosis-program-in-rd-webinar?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/immunic-highlights-multiple-sclerosis-program-in-rd-webinar?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","IMUX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664801260","title":"Immunic Posts Investor Overview Presentation on Multiple Sclerosis Strategy","url":"https://stock-news.laohu8.com/highlight/detail?id=2664801260","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664801260?lang=en_us&edition=fundamental","pubTime":"2026-09-04 04:33","pubTimestamp":1788467599,"startTime":"0","endTime":"0","summary":"Immunic posts investor overview presentation on multiple sclerosis strategyImmunic published an investor overview highlighting vidofludimus calcium (IMU-838) as an oral multiple sclerosis therapy with","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260903:nNDL8GSv0h:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","IMUX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664813167","title":"Immunic to Host Virtual Relapsing Multiple Sclerosis R&D Day","url":"https://stock-news.laohu8.com/highlight/detail?id=2664813167","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664813167?lang=en_us&edition=fundamental","pubTime":"2026-09-02 18:30","pubTimestamp":1788345035,"startTime":"0","endTime":"0","summary":"Immunic to host virtual relapsing multiple sclerosis R&D dayImmunic will host a virtual relapsing multiple sclerosis R&D Day on Sept. 9, 2026.Webinar scheduled for 11:00 a.m. to 12:30 p.m. ET via Zoom","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260902:nNDL21J14D:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IMUX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.imux.com","stockEarnings":[{"period":"1week","weight":0.0135},{"period":"1month","weight":-0.1925},{"period":"3month","weight":-0.4624},{"period":"6month","weight":-0.2218},{"period":"1year","weight":-0.0423},{"period":"ytd","weight":0.4072}],"compareEarnings":[{"period":"1week","weight":-0.0056},{"period":"1month","weight":-0.0091},{"period":"3month","weight":0.0116},{"period":"6month","weight":0.0487},{"period":"1year","weight":0.1116},{"period":"ytd","weight":0.1082}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Immunic, Inc., a clinical-stage biopharmaceutical company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases. Its lead development program is IMU-838, which is in Phase 3 clinical for treatment of multiple sclerosis, including relapsing multiple sclerosis and other chronic inflammatory and autoimmune diseases, as well as to treat coronavirus disease. The company is also developing IMU-935, an inverse agonist of retinoic acid receptor-related orphan nuclear receptor gamma truncated; and IMU-856 for the restoration of the intestinal barrier function in patients suffering from diseases, such as celiac disease, inflammatory bowel disease, irritable bowel syndrome with diarrhea, and other intestinal barrier function diseases. Immunic, Inc. is headquartered in New York, New York.","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":0.061205},{"month":2,"riseRate":0.416667,"avgChangeRate":0.061188},{"month":3,"riseRate":0.333333,"avgChangeRate":-0.034042},{"month":4,"riseRate":0.25,"avgChangeRate":0.025838},{"month":5,"riseRate":0.166667,"avgChangeRate":-0.041432},{"month":6,"riseRate":0.615385,"avgChangeRate":0.126262},{"month":7,"riseRate":0.538462,"avgChangeRate":0.043068},{"month":8,"riseRate":0.615385,"avgChangeRate":-0.028789},{"month":9,"riseRate":0.461538,"avgChangeRate":-0.099452},{"month":10,"riseRate":0.307692,"avgChangeRate":-0.047405},{"month":11,"riseRate":0.5,"avgChangeRate":-0.001684},{"month":12,"riseRate":0.583333,"avgChangeRate":0.021046}],"exchange":"NASDAQ","name":"Immunic, Inc.","nameEN":"Immunic, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.52.1","shortVersion":"4.52.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Immunic, Inc.(IMUX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Immunic, Inc.(IMUX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Immunic, Inc.,IMUX,Immunic, Inc.股票,Immunic, Inc.股票老虎,Immunic, Inc.股票老虎国际,Immunic, Inc.行情,Immunic, Inc.股票行情,Immunic, Inc.股价,Immunic, Inc.股市,Immunic, Inc.股票价格,Immunic, Inc.股票交易,Immunic, Inc.股票购买,Immunic, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Immunic, Inc.(IMUX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Immunic, Inc.(IMUX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}